This is an automatically translated article.
Fabacoem 500 is a drug used to treat excess iron in the body mainly in Thalassemia patients. Drugs are indicated when traditional therapies are not effective.
1. What is Fabacoem 500?
Fabacoem 500 has the main ingredient Deferiprone with the chemical formula 3-hydroxy-1,2-dimethylpyridin-4-one, which is a bivalent carrier that combines with iron in a molecular ratio 3:1. Deferiprone is effective in promoting iron excretion and preventing iron stagnation in the form of serum ferritin, in transfusion-dependent thalassemia patients.
The drug is quickly absorbed from the gastrointestinal tract, after entering the body Fabacoem 500 is metabolized in the liver and eliminated in the urine.
2. Indications of Fabacoem 500
Fabacoem 500 is indicated for the treatment of iron overload due to frequent transfusion therapy in patients with thalassemia for whom iron-removal therapy (deferoxamine) is inadequate or contraindicated.3. Contraindications of Fabacoem 500
Fabacoem 500 should not be used in the following cases:
Allergy to Deferiprone or any other ingredient of the drug. Neutrophils recur frequently. Patients with a history of or current agranulocytosis. Pregnant and lactating women should not use the drug because it crosses the placenta and breast milk. Precautions when using Fabacoem 500
Fabacoem 500 reduces neutrophils including agranulocytosis. Patients forced to take medication need to check and monitor blood counts weekly. Patients with renal impairment or liver dysfunction should use caution when taking the drug because it is metabolized in the liver and eliminated in the urine. When taking the drug, the urine may turn slightly red or brown due to the elimination of the iron-deferiprone complex. Women who are planning to become pregnant or are pregnant take drugs that are at risk of causing genetic mutations and birth defects.
4. Interactions of drugs Fabacoem 500
Possible interactions of Fabacoem 500 with other drugs are as follows:
Fabacoem 500 can bind with trivalent metal cations such as aluminum to change the effect of the drug. Several drug interactions can occur when Fabacoem 500 is taken with vitamin C. Co-administration of Fabacoem 500 with drugs that reduce neutrophils or agranulocytosis increases the risk of agranulocytosis.
5. Dosage and how to use Fabacoem 500
How to use: Fabacoem 500 is taken orally. The patient should take the tablet whole with a sufficient amount of water. The effect of the drug is independent of food.
Dosage:
Starting dose: 25mg/kg x 3 times/day. The maximum dose is 100mg/kg/day. (Doses above 100mg/kg/day can cause many unwanted side effects). Children from 6 to 10 years old limited indication. Do not use for children under 6 years old.
6. Side effects of Fabacoem 500
When using Fabacoem 500, patients may experience some unwanted effects as follows:
Agranulocytosis. Diarrhea . Mild pain in one or more joints, arthritis with effusion Decreased serum zinc levels due to binding to Fabacoem 500. In summary, Fabacoem 500 is indicated for the treatment of iron overload due to continuous transfusion therapy in patients Thalassemia . This is a mandatory prescription drug and should be used under the strict supervision of a doctor. Patients need to follow the instructions exactly to ensure effectiveness and avoid unwanted side effects.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
